CN109957547A

CN109957547A - A kind of Chimeric antigen receptor T cell and its preparation method and application targeting CD317

Info

Publication number: CN109957547A
Application number: CN201711419867.0A
Authority: CN
Inventors: 张宏玲; 龙丽梅; 钟春颖
Original assignee: Shenzhen Benta Biological Technology Co Ltd
Current assignee: Shenzhen Benta Biological Technology Co Ltd
Priority date: 2017-12-25
Filing date: 2017-12-25
Publication date: 2019-07-02

Abstract

The present invention provides a kind of Chimeric antigen receptor T cells for targeting CD317, Chimeric antigen receptor CAR-CD317 including targeting CD317, CAR-CD317 include from aminoterminal to c-terminus the sequentially connected targeting single-chain antibody of CD317, extracellular hinge area, transmembrane region and intracellular signal area amino acid sequence, the single-chain antibody for targeting CD317 includes the amino acid sequence as shown in SEQ ID NO:1, intracellular signal area includes sequentially connected CD27 signaling zone and CD3 ζ signaling zone, and CD27 signaling zone includes the amino acid sequence as shown in SEQ ID NO:2.CAR-CD317 can target CD317 in specific manner, promote T cell in the amplification of patient's body, efficiently and specifically killing tumor cell.The present invention also provides the preparation method and application of the T cell.

Description

A kind of Chimeric antigen receptor T cell and its preparation method and application targeting CD317

Technical field

The present invention relates to field of medical biotechnology, in particular to a kind of Chimeric antigen receptor T cell and its system for targeting CD317 Preparation Method and application.

Background technique

Malignant tumour (cancer) has become the arch-criminal for threatening human life, and disease incidence is at ascendant trend.CD317 is Lipid Rafts phase Albumen is closed, main expression is on a variety of solid tumor cells such as liver cancer, colon cancer, and the almost seldom expression in ordinary cells. The expression of CD317 is often that cell shows the response of gamma- interferon access, therefore has substantial connection with tumour.

CAR-T (Chimeric antigen receptor T cell) technology is a kind of novel cell therapy, it is that the T by CAR transformation is thin Born of the same parents are fed back to human body, activate self immune system, kill to tumour cell, it is considered to be current most effective malignant tumour One of therapeutic modality.But the application of current CAR-T technology is also limited to blood tumor, to a variety of solid tumors such as liver cancer do not have also into Exhibition.In addition, CAR-T cell is the guarantee of CAR-T long-term efficacy in body maintenance ability (persistence), but actually CAR-T a few days to a few weeks after feedback just completely disappear, and fail to play the ability of long-acting lasting killing tumor cell.

Summary of the invention

In view of this, the present invention provides a kind of Chimeric antigen receptor T cell for targeting CD317, including targeting CD317's Chimeric antigen receptor CAR-CD317,.The Chimeric antigen receptor of the targeting CD317 can target CD317 in specific manner, promote T Cell is in the amplification of patient's body, efficiently and specifically killing tumor cell, and hardly causes to damage to normal cell. The Chimeric antigen receptor T cell of Humanized single chain antibody targeting CD317 obtained can enduringly maintain its self-renewing simultaneously Ability and tumor-killing power.The present invention also provides a kind of preparation method of Chimeric antigen receptor T cell for targeting CD317 and answer With.

In a first aspect, the present invention provides a kind of Chimeric antigen receptor T cell for targeting CD317, including targeting CD317's Chimeric antigen receptor CAR-CD317, the CAR-CD317 include the sequentially connected targeting CD317 from aminoterminal to c-terminus Single-chain antibody, extracellular hinge area, transmembrane region and intracellular signal area amino acid sequence, wherein the targeting CD317's is single-stranded anti- Body includes the amino acid sequence as shown in SEQ ID NO:1, and the intracellular signal area includes sequentially connecting from aminoterminal to c-terminus The CD27 signaling zone and CD3 ζ signaling zone connect, the amino acid sequence of the CD27 signaling zone include as shown in SEQ ID NO:2 Amino acid sequence.

Wherein, described " being sequentially connected with from aminoterminal to c-terminus " specifically: the ammonia of the single-chain antibody of the targeting CD317 The c-terminus of base acid sequence is connected with the aminoterminal of the amino acid sequence of the hinge area, the amino acid sequence of the extracellular hinge area The c-terminus of column is connected with the aminoterminal of the amino acid sequence of the transmembrane region, the c-terminus of the amino acid sequence of the transmembrane region It is connected with the aminoterminal of the amino acid sequence in the intracellular signal area.

Optionally, the encoding gene of the single-chain antibody of the targeting CD317 includes the nucleotide as shown in SEQ ID NO:6 Sequence.

Optionally, the single-chain antibody encoding gene of the targeting CD317 should consider degeneracy base, i.e., such as SEQ ID NO: The encoding gene of amino acid sequence shown in 1 includes the nucleotide sequence as shown in SEQ ID NO:6, and protection scope should also be protected Shield has the nucleotide sequence of base degeneracy matter with SEQ ID NO:6, and the corresponding amino acid sequence of these nucleotide sequences is still It is so SEQ ID NO:1.

In the present invention, the extracellular hinge area is used to promote the CD317 on the single-chain antibody and tumour of the targeting CD317 In conjunction with.Optionally, the extracellular hinge area includes CD8 α hinge area, CD28 hinge area, CD4 hinge area, CD5 hinge area, CD134 One of hinge area, CD137 hinge area, ICOS hinge area or a variety of combinations.It is further alternative, the extracellular hinge area For CD8 α hinge area.

Optionally, the amino acid sequence of the CD8 α hinge area includes the amino acid sequence as shown in SEQ ID NO:7.

Optionally, the encoding gene of the CD8 α hinge area includes the nucleotide sequence as shown in SEQ ID NO:8.

Optionally, the encoding gene of the CD8 α hinge area should consider degeneracy base, i.e., as shown in SEQ ID NO:6 The encoding gene of amino acid sequence includes the nucleotide sequence as shown in SEQ ID NO:8, and protection scope should also protect and SEQ ID NO:7 has the nucleotide sequence of base degeneracy matter, and the corresponding amino acid sequence of these nucleotide sequences remains as SEQ ID NO:7。

In the present invention, the transmembrane region is used to fix the Chimeric antigen receptor CAR-CD317 of the targeting CD317.It is optional , the transmembrane region includes one of CD3 transmembrane region, CD4 transmembrane region, CD8 transmembrane region, CD28 transmembrane region or a variety of groups It closes.Further alternative, the transmembrane region is CD8 transmembrane region.

Optionally, the amino acid sequence of the CD8 transmembrane region includes the amino acid sequence as shown in SEQ ID NO:9.

Optionally, the encoding gene of the CD8 transmembrane region includes the nucleotide sequence as shown in SEQ ID NO:10.

Optionally, the encoding gene of the CD8 transmembrane region should consider degeneracy base, i.e., as shown in SEQ ID NO:8 The encoding gene of amino acid sequence include the nucleotide sequence such as SEQ ID NO:10 shown in, protection scope should also protect and SEQ ID NO:10 has the nucleotide sequence of base degeneracy matter, and the corresponding amino acid sequence of these nucleotide sequences remains as SEQ ID NO:9。

In the present invention, the intracellular signal area for providing the signal of T cell activation, maintain T cell life span and Activate T cell proliferation signal access.Optionally, the intracellular signal area includes 4-1BB signaling zone, CD3 ζ signaling zone, ICOS letter Number area, CD27 signaling zone, OX40 signaling zone, CD28 signaling zone, IL1R1 signaling zone, CD70 signaling zone, TNFRSF19L signaling zone One of or a variety of combinations.

In the present invention, the intracellular signal Qu Weicong aminoterminal to the sequentially connected CD27 signaling zone of c-terminus and CD3 ζ letter Number area.

Optionally, the amino acid sequence of the CD27 signaling zone includes the amino acid sequence as shown in SEQ ID NO:2.

Optionally, the encoding gene of the CD27 signaling zone includes the nucleotide sequence as shown in SEQ ID NO:11.

Optionally, the encoding gene of the CD27 signaling zone should consider degeneracy base, i.e., as shown in SEQ ID NO:10 Amino acid sequence encoding gene include the nucleotide sequence such as SEQ ID NO:11 shown in, protection scope should also protect and SEQ ID NO:11 has the nucleotide sequence of base degeneracy matter, and the corresponding amino acid sequence of these nucleotide sequences remains as SEQ ID NO:10。

Optionally, the amino acid sequence of the CD3 ζ signaling zone includes the amino acid sequence as shown in SEQ ID NO:12.

Optionally, the encoding gene of the CD3 ζ signaling zone includes the nucleotide sequence as shown in SEQ ID NO:13.

Optionally, the encoding gene of the CD3 ζ signaling zone should consider degeneracy base, i.e., as shown in SEQ ID NO:12 Amino acid sequence encoding gene include the nucleotide sequence such as SEQ ID NO:13 shown in, protection scope should also protect and SEQ ID NO:13 has the nucleotide sequence of base degeneracy matter, and the corresponding amino acid sequence of these nucleotide sequences remains as SEQ ID NO:12。

Optionally, the amino acid sequence of the CAR-CD317 includes the amino acid sequence as shown in SEQ ID NO:3.

Optionally, the encoding gene of the CAR-CD317 includes the nucleotide sequence as shown in SEQ ID NO:4.

Optionally, the encoding gene of the CAR-CD317 should consider degeneracy base, i.e., as shown in SEQ ID NO:3 The encoding gene of amino acid sequence includes the nucleotide sequence as shown in SEQ ID NO:4, and protection scope should also protect and SEQ ID NO:4 has the nucleotide sequence of base degeneracy matter, and the corresponding amino acid sequence of these nucleotide sequences remains as SEQ ID NO:3。

The Chimeric antigen receptor T cell for the targeting CD317 that first aspect present invention provides, including targeting CD317's Chimeric antigen receptor CAR-CD317, this receptor for T cell targeted expression CD317 in specific manner tumour cell, After CAR-CD317 is in conjunction with CD317, the intracellular signal area of the T cell is activated, promote T cell patient's body amplification, And efficient and specific killing tumor cell, and normal cell is hardly caused to damage.Moreover, such as SEQ ID NO:2 Amino acid sequence shown in costimulatory signal of the CD27 signaling zone as the T cell, it is special with the antigen as T cell at it Under the collective effect of the CD3 ζ signaling zone of specific signal (that is, first signal), T cell is activated completely after identifying antigen.It is special Not, select the CD27 signaling zone such as SEQ ID NO:2 that can preferably promote the expansion of subsequent T cell as costimulatory signal Energization power, killing vigor.

In addition, the single-chain antibody of targeting CD317 is Humanized single chain antibody, this makes the inosculating antibody of the targeting CD317 Original receptor T cell avoids the immune response for causing human organism, maintains ability (including vigor and lethality) in body with lasting.

Second aspect, the present invention provides a kind of recombinant viral vector, the recombinant viral vector includes such as second aspect The encoding gene of the CAR-CD317 of the Chimeric antigen receptor T cell of the targeting CD317.

Preferably, the encoding gene of the CAR-CD317 includes the nucleotide sequence as shown in SEQ ID NO:5.Such as SEQ Nucleotide sequence shown in ID NO:5 is compared with the nucleotide sequence as shown in SEQ ID NO:4, more coding bases of link peptide Cause.The encoding gene of the signal peptide can be expressed with Chimeric antigen receptor CAR-CD317 described in guide to cell surface.

Optionally, the viral vectors in the recombinant viral vector includes slow virus carrier, adenovirus vector or reverse transcription Viral vectors.

Further alternative, the viral vectors is slow virus carrier.

The recombinant viral vector that second aspect of the present invention provides has very high efficiency of infection and transcriptional efficiency, inserts The CAR-CD317 encoding gene segment entered can be inserted into host genome by genetic recombination, obtain the chimeric antigen of targeting CD317 Recipient T cells, to make it continue, the Chimeric antigen receptor CAR-CD317 of steadily expression targeting CD317.

The third aspect, the present invention provides a kind of host cell, the host cell includes the weight as described in the third aspect Group viral vectors.

The host cell is used to assemble the recombinant viral vector as described in the third aspect, makes it have infectivity.

Optionally, the host cell may include HEK293T cell, 293 cells, 293T cell, 293FT cell, SW480 cell, u87MG cell, HOS cell, COS1 cell or COS7 cell etc., but not limited to this.

Further alternative, the host cell is HEK293T cell.

Fourth aspect, the present invention provides a kind of preparation methods of Chimeric antigen receptor T cell for targeting CD317, comprising:

(1) encoding gene of the Chimeric antigen receptor CAR-CD317 of targeting CD317 is provided, including suitable from 5 ' ends to 3 ' ends The encoding gene of the signal peptide of secondary connection, the encoding gene of single-chain antibody for targeting CD317, extracellular hinge area encoding gene, The encoding gene of transmembrane region and the encoding gene in intracellular signal area；Wherein, the single-chain antibody of the targeting CD317 is humanization list Chain antibody, the encoding gene of the single-chain antibody of the targeting CD317 include coding amino acid sequence as shown in SEQ ID NO:1 Nucleotide sequence；The encoding gene in the intracellular signal area includes the volume from 5 ' ends to 3 ' the sequentially connected CD27 signaling zones in end The encoding gene of code gene and CD3 ζ signaling zone, the encoding gene of the CD27 signaling zone include coding such as SEQ ID NO:2 institute The nucleotide sequence of the amino acid sequence shown；

(2) encoding gene of the CAR-CD317 is inserted into pWPXLD carrier, obtains pWPXLD-CAR-CD317 weight Group plasmid；

(3) it by the pWPXLD-CAR-CD317 recombinant plasmid and envelope plasmid, packaging plasmid cotransfection host cell, obtains To recombinant slow virus；

(4) recombinant slow virus is transfected into CD3 positive t lymphocytes, obtains the Chimeric antigen receptor T of targeting CD317 Cell.

It is above-mentioned " from 5 ' end to 3 ' end be sequentially connected with " specifically: the coding gene sequence of the signal peptide 3 ' end with it is described 5 ' the ends for targeting the coding gene sequence of the single-chain antibody of CD317 are connected, the encoding gene of the single-chain antibody of the targeting CD317 3 ' ends of sequence are connected with 5 ' ends of the coding gene sequence of the extracellular hinge area, the encoding gene sequence of the extracellular hinge area 3 ' ends of column are connected with the 5 ' of the coding gene sequence of transmembrane region ends, the 3 ' of the coding gene sequence of the transmembrane region hold and 5 ' ends of the coding gene sequence in the intracellular signal area are connected.

The signal peptide is used to that the Chimeric antigen receptor CAR-CD317 to be instructed to express to cell surface in the present invention, The signal peptide is cut in protein translation maturation by signal peptidase.

Optionally, the amino acid sequence of the signal peptide includes the amino acid sequence as shown in SEQ ID NO:14.

Optionally, the encoding gene of the signal peptide includes the nucleotide sequence as shown in SEQ ID NO:15.

Optionally, the coding gene sequence of the signal peptide should consider degeneracy base, i.e., as shown in SEQ ID NO:14 Amino acid sequence encoding gene include the nucleotide sequence such as SEQ ID NO:15 shown in, protection scope should also protect and SEQ ID NO:15 has the nucleotide sequence of base degeneracy matter, and the corresponding amino acid sequence of these nucleotide sequences remains as SEQ ID NO:14。

It, can for the extracellular hinge area, transmembrane region, the specific choice in intracellular signal area and corresponding coding gene sequence Referring to the description of first aspect present invention part, which is not described herein again.

Optionally, the encoding gene of the CAR-CD317 includes the nucleotide sequence as shown in SEQ ID NO:5.Such as SEQ Nucleotide sequence shown in ID NO:5 is compared with the nucleotide sequence as shown in SEQ ID NO:4, more volumes of the link peptide Code gene, but when Chimeric antigen receptor CD317 expression is to cell surface, the signal peptide is in protein translation maturation It is middle to be cut by signal peptidase.Therefore, the not band in the amino acid sequence of the Chimeric antigen receptor CAR-CD317 translated into Just like amino acid sequence shown in SEQ ID NO:14.

The coding gene sequence of the CAR-CD317 be inserted into pWPXLD carrier BamH I and I restriction enzyme site of EcoR it Between, and be located at after the extension factor 1 α (EF1 α) of pWPXLD carrier, using EF1 α as promoter.The gene of the CAR-CD317 When sequence is inserted into pWPXLD carrier, initiation codon (such as ATG) can be also added in 5 ' ends of the gene order of the CAR-CD317 It is connected with BamH1 restriction enzyme site in pWPXLD carrier, EcoR1 digestion in terminator codon and pWPXLD carrier can be also added in 3 ' ends Site is connected.

Optionally, the envelope plasmid is PMD2G, and the packaging plasmid is psPAX2, and the host cell is HEK293T Cell.

The envelope plasmid PMD2G encodes vesicular stomatitis virus glycoprotein capsid, the vesicular stomatitis virus sugar egg White capsid can assist recombinant slow virus to adhere to cell membrane, and keep the infectivity of recombinant slow virus.

Recombinant slow virus of the present invention can further contain the envelope protein from other viruses.For example, as this Kind protein, is preferably the virus enveloped protein for carrying out self-infection human cell.To this protein, there is no particular limitation, can example The amphophilic virus hand epithelium albumen etc. for enumerating retrovirus, can be used for example from mouse leukemia virus (MuMLV) 4070A plants of envelope protein.Alternatively, it is also possible to use the envelope protein from MuMLV 10Al.In addition, as herpetoviridae Albumen, it can be cited for example that, gB, gD, gH, gp85 albumen of herpes simplex virus, gp350, gp220 albumen of Epstein-Barr virus Deng.As the albumen of Hepadna Virus section, the S protein etc. of hepatitis B virus can be included.The envelope protein can also be morbilli It is formed after viral glycoprotein and other single chain antibody fusions.

The packaging of recombinant slow virus is generallyd use transient transfection or is packed using cell line.It may be used as wrapping when transient transfection Human cell's strain that dress cell uses, for example including 293 cells, 293T cell, 293FT cell, 293LTV cell, 293EBNA Cell and other clones separated from 293 cells；SW480 cell, u87MG cell, HOS cell, C8166 cell, MT-4 are thin Born of the same parents, Molt-4 cell, HeLa cell, HT1080 cell, TE671 cell etc..It can also be using the cell strain from monkey, example Such as, COS1 cell, COS7 cell, CV-1 cell, BMT10 cell etc..Moreover, the calcium phosphate and PEI transfection reagent that generally use, It is also well used there are also some transfection reagents such as Lipofectamine2000, FuGENE and S93fectin.

The packaging of recombinant slow virus also uses some slow virus package cell lines, such as most common Env glycoprotein of use, Stable cell lines caused by VSVG albumen or HIV-1gag-pol albumen.

For the sake of security, the slow virus carrier system of large-scale use is all the method using split gene group, i.e., will The assignment of genes gene mapping of different miscellaneous functions is played in different plasmids.There are four pUC pUCs (encoding gag-pol gene, Rev base at present Cause, VSVG gene, SIN metastatic gene be located at four different plasmids), three pUC pUCs (eliminate coding Rev gene Plasmid, gag-pol gene uses the codon of the preferences in people's cell in gag-pol plasmid) and two pUC pUCs are (slowly Auxiliary gene necessary to viral vectors is packed is located on the same plasmid, these auxiliary genes are single gene orders；Separately One is then transgenosis plasmid).Also the slow virus packaging system for having more than four pUC pUCs is using.

Optionally, in step (4), the CD3 positive t lymphocytes are to separate to obtain from source of people peripheral blood mononuclear cells ?.

Optionally, the source of people peripheral blood mononuclear cells derives from autologous vein blood, autologous bone marrow, Cord blood and placenta Blood etc..It is further alternative, from cancer patient perform the operation one month after, the fresh peripheral blood that acquires after chemicotherapy one month or Marrow.

Specifically, the acquisition process of the CD3 positive t lymphocytes is as follows: into peripheral blood mononuclear cells by certain CD3/CD28 immunomagnetic beads are added in ratio, after being incubated for a period of time, are put into magnet and are screened, it is coated to obtain immunomagnetic beads CD3 positive t lymphocytes after removing magnetic bead, obtain CD3 positive t lymphocytes.

5th aspect, the present invention provides it is a kind of as described in relation to the first aspect or preparation method system as described in fourth aspect The targeting Chimeric antigen receptor T cell of CD317, the recombinant viral vector as described in second aspect or as described in the third aspect Host cell in preparation prevention, the application in diagnosing and treating malignant tumor medicine.Tumour suitable for expressing CD317 is examined Disconnected and treatment etc., such as the solid tumors such as liver cancer, colon cancer, cervical carcinoma.

The application specifically: provide a kind of kit, the kit includes targeting as described in relation to the first aspect The Chimeric antigen receptor T cell of CD317, the recombinant viral vector as described in second aspect, the host as described in the third aspect are thin One of born of the same parents are a variety of.

Advantages of the present invention will be illustrated partially in the following description, and a part is apparent according to specification , or can implementation through the embodiment of the present invention and know.

Detailed description of the invention

Fig. 1 is the plasmid map of pWPXLd-CAR-CD317 recombinant plasmid provided in an embodiment of the present invention.

Specific embodiment

The following is a preferred embodiment of the present invention, it is noted that for those skilled in the art For, various improvements and modifications may be made without departing from the principle of the present invention, these improvements and modifications are also considered as Protection scope of the present invention.

Embodiment one

A kind of preparation method for the Chimeric antigen receptor T cell targeting CD317, comprising the following steps:

(1) gene order of the Chimeric antigen receptor CAR-CD317 of preparation targeting CD317

Prepare respectively signal peptide, target the single-chain antibody of CD317, CD8 α hinge area, CD8 transmembrane region, CD27 signaling zone and The encoding gene of CD3 ζ signaling zone, the coding gene sequence of the signal peptide is as shown in SEQ ID NO:15, the targeting CD317 Single-chain antibody coding gene sequence as shown in SEQ ID NO:2, the coding gene sequence such as SEQ of the CD8 α hinge area Shown in ID NO:7, the coding gene sequence of the CD8 transmembrane region is as shown in SEQ ID NO:9, the coding of the CD27 signaling zone Gene order is as shown in SEQ ID NO:11, and the encoding gene of the CD3 ζ signaling zone is as shown in SEQ ID NO:13.

By the method for PCR by above-mentioned signal peptide, the single-chain antibody for targeting CD317, CD8 α hinge area, CD8 transmembrane region, CD27 signaling zone is successively connected together from 5 ' ends to 3 ' ends with the coding gene sequence of CD3 ζ signaling zone, obtains targeting CD317 Chimeric antigen receptor CAR-CD317 encoding gene, the coding gene sequence of the CAR-CD317 such as SEQ ID NO:5 institute Show, wherein the single-chain antibody of the targeting CD317 is Humanized single chain antibody.

(2) pWPXLd-CAR-CD317 recombinant plasmid is constructed

The coding gene sequence of CAR-CD317 is inserted between BamH1 the and EcoR1 restriction enzyme site of pWPXLD carrier, And after pWPXLD carrier EF1 α, using EF1 α as promoter.The coding gene sequence of the CAR-CD317 is inserted into pWPXLD When carrier, 5 ' ends of the coding gene sequence of the CAR-CD317 are added in initiation codon (such as ATG) and pWPXLD carrier BamH1 restriction enzyme site is connected, and 3 ' ends are also connected added with terminator codon with EcoR1 restriction enzyme site in pWPXLD carrier.Then It is transferred to competent escherichia coli cell DH5 α, carries out positive colony PCR identification and sequencing identification.By PCR product gel electrophoresis Detection and sequencing identification meet target fragment size and sequence, successfully construct pWPXLd-CAR-CD317 recombination as shown in Figure 1 Plasmid.

(3) recombinant slow virus constructs

PWPXLd-CAR-CD317 recombinant plasmid, packaging plasmid psPAX2, envelope plasmid pMD2G three cotransfection are entered into training The HEK293T cell supported.48h harvest is protected in -80 DEG C of ultra low temperature freezers containing the supernatant of virus through 0.45 μm of membrane filtration It deposits；Supernatant of the 72h aftercrop containing virus, 0.45 μm of membrane filtration add together after merging with the viral supernatants of 48h harvest Enter in the centrifuge tube that exceeds the speed limit, be put into Beckman ultracentrifuge one by one, setting parameter of noncentricity is 25000rpm, centrifugation time For 2h, centrifuging temperature is controlled at 4 DEG C；It after centrifugation, discards supernatant, removal as far as possible remains in the liquid on tube wall, and disease is added Poison saves liquid, and gently piping and druming is resuspended repeatedly；Through after completely dissolution, high speed centrifugation 10000rpm takes supernatant fluorescence after being centrifuged 5min Method measures titre, and virus is according to 100 μ l, and 2 × 10⁸A/mL packing, is stored in -80 DEG C of ultra low temperature freezers, obtains recombinant lentiviral disease Poison.

(4) preparation of the Chimeric antigen receptor T cell of CD317 is targeted

A) separation of PBMC (peripheral blood mononuclear cells)

PBMC is from autologous vein blood, autologous bone marrow, Cord blood and placental blood etc..Preferably derive from cancer patient's hand The fresh peripheral blood or marrow acquired after art one month, after chemicotherapy one month.

Extract patient blood, sample presentation to blood separating chamber；Peripheral blood mononuclear cells is acquired, is taken after Ficoll centrifuge separation Intermediate layer cell；After PBS is washed, PBMC is obtained.

B) immunomagnetic beads antigenspecific T lymphocyte

Above-mentioned PBMC is taken, the basal medium for being free of serum is added, is made into cell suspension；Ratio in magnetic bead and cell is 3:1, is added CD3/CD28 immunomagnetic beads, and room temperature incubates 1-2h；The cell for being incubated for magnetic bead is screened using magnet；To screening Cell out removes magnetic bead, and PBS washing obtains CD3 positive t lymphocytes.

C) virus transfection method prepares antigenspecific T lymphocyte

The above-mentioned CD3 positive t lymphocytes obtained by magnetic activated cell seperation are taken, are added and CD3 positive cell number phase The recombinant slow virus for the virus titer answered is cultivated.

The 3rd day of culture carries out cell count and changes liquid, and adjustment cell concentration is 1 × 10⁶A/mL is inoculated with, culture；Training Cell state is observed in feeding the 5th day, if cell density increases, diluting cells concentration is 1 × 10⁶A/mL detects cell Activity continues to cultivate.Amplification cultivation collected cell by the 9-11 days, obtained the Chimeric antigen receptor T cell of targeting CD317, and It is stored in and feeds back in dedicated cells frozen storing liquid, used so that patient feeds back.

The embodiments described above only express several embodiments of the present invention, and the description thereof is more specific and detailed, but simultaneously Limitations on the scope of the patent of the present invention therefore cannot be interpreted as.It should be pointed out that for those of ordinary skill in the art For, without departing from the inventive concept of the premise, various modifications and improvements can be made, these belong to guarantor of the invention Protect range.Therefore, the scope of protection of the patent of the invention shall be subject to the appended claims.

Sequence table

<110>Shenzhen Bin De Bioisystech Co., Ltd

<120>a kind of Chimeric antigen receptor T cell and its preparation method and application for targeting CD317

<160> 15

<170> SIPOSequenceListing 1.0

<210> 1

<211> 243

<212> PRT

<213>artificial sequence (Artificial Sequence)

<400> 1

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Thr Phe Ser Asp Tyr

20 25 30

Tyr Met Ala Trp Val Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu

35 40 45

Gly Leu Ile Arg Asn Lys Gly Asn Gly Tyr Thr Thr Glu His Ser Ala

50 55 60

Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Gln Ser Ile

65 70 75 80

Leu Tyr Leu Gln Met Asn Thr Leu Arg Pro Glu Asp Ser Ala Thr Tyr

85 90 95

Tyr Cys Ala Arg Asp Tyr Arg Ser Met Asp Tyr Trp Gly Ala Gly Thr

100 105 110

Ile Val Thr Val Asn Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly

115 120 125

Gly Gly Gly Ser Asp Ile Val Leu Thr Gln Ser Thr Pro Ser Leu Ala

130 135 140

Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser

145 150 155 160

Val Asp Ser Tyr Gly Asn Ser Phe Met His Trp Phe Gln Gln Lys Pro

165 170 175

Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser

180 185 190

Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr

195 200 205

Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys

210 215 220

Gln Gln Ser Asn Glu Asp Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu

225 230 235 240

Glu Ile Lys

<210> 2

<211> 46

<212> PRT

<213>artificial sequence (Artificial Sequence)

<400> 2

Arg Lys Tyr Arg Ser Asn Lys Gly Glu Ser Pro Val Glu Pro Ala Glu

1 5 10 15

Pro Cys Arg Tyr Ser Cys Pro Arg Glu Glu Glu Gly Ser Thr Ile Pro

20 25 30

Ile Gln Glu Asp Tyr Arg Lys Pro Glu Pro Ala Cys Ser Pro

35 40 45

<210> 3

<211> 470

<212> PRT

<213>artificial sequence (Artificial Sequence)

<400> 3

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Thr Phe Ser Asp Tyr

20 25 30

Tyr Met Ala Trp Val Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu

35 40 45

Gly Leu Ile Arg Asn Lys Gly Asn Gly Tyr Thr Thr Glu His Ser Ala

50 55 60

Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Gln Ser Ile

65 70 75 80

Leu Tyr Leu Gln Met Asn Thr Leu Arg Pro Glu Asp Ser Ala Thr Tyr

85 90 95

Tyr Cys Ala Arg Asp Tyr Arg Ser Met Asp Tyr Trp Gly Ala Gly Thr

100 105 110

Ile Val Thr Val Asn Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly

115 120 125

Gly Gly Gly Ser Asp Ile Val Leu Thr Gln Ser Thr Pro Ser Leu Ala

130 135 140

Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser

145 150 155 160

Val Asp Ser Tyr Gly Asn Ser Phe Met His Trp Phe Gln Gln Lys Pro

165 170 175

Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser

180 185 190

Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr

195 200 205

Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys

210 215 220

Gln Gln Ser Asn Glu Asp Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu

225 230 235 240

Glu Ile Lys Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro

245 250 255

Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro

260 265 270

Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp

275 280 285

Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu

290 295 300

Ser Leu Val Ile Thr Leu Tyr Cys Arg Lys Tyr Arg Ser Asn Lys Gly

305 310 315 320

Glu Ser Pro Val Glu Pro Ala Glu Pro Cys Arg Tyr Ser Cys Pro Arg

325 330 335

Glu Glu Glu Gly Ser Thr Ile Pro Ile Gln Glu Asp Tyr Arg Lys Pro

340 345 350

Glu Pro Ala Cys Ser Pro Arg Val Lys Phe Ser Arg Ser Ala Asp Ala

355 360 365

Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu

370 375 380

Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp

385 390 395 400

Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu

405 410 415

Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile

420 425 430

Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr

435 440 445

Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met

450 455 460

Gln Ala Leu Pro Pro Arg

465 470

<210> 4

<211> 1410

<212> DNA

<213>artificial sequence (Artificial Sequence)

<400> 4

gaggtgaagc tggtggagtc tggaggaggc ttggtacagc ctgggggttc tctgagactc 60

tcctgtgcaa cttctgggtt cacgttctct gattactaca tggcctgggt ccgccagcct 120

ccaggaaagg cacttgagtg gttgggttta attagaaaca aaggtaatgg ttacacaaca 180

gagcacagtg catctgtgag gggtcggttc accatctcca gagataattc ccaaagcatc 240

ctctatcttc aaatgaacac cctgagacct gaggacagtg ccacttatta ctgtgcaaga 300

gattaccggt ctatggacta ctggggcgca ggaactatag tcacagtcaa tggtggcggt 360

ggctcgggcg gtggtgggtc gggtggcggc ggatctgaca ttgtgctcac acaatctaca 420

ccttctttgg ctgtgtctct agggcagagg gccaccatat cctgcagagc cagtgaaagt 480

gttgatagtt atggcaacag ttttatgcac tggttccagc agaaaccagg acagccaccc 540

aaactcctca tctatcgtgc atccaaccta gaatctggga tccctgccag gttcagtggc 600

agtgggtcta ggacagactt caccctcacc attaatcctg tggaggctga tgatgttgca 660

acctattact gtcagcaaag taatgaggat ccgtacacgt tcggaggggg gaccaagctg 720

gaaataaaaa ccacgacgcc agcgccgcga ccaccaacac cggcgcccac catcgcgtcg 780

cagcccctgt ccctgcgccc agaggcgtgc cggccagcgg cggggggcgc agtgcacacg 840

agggggctgg acttcgcctg tgatatctac atctgggcgc ccttggccgg gacttgtggg 900

gtccttctcc tgtcactggt tatcaccctt tactgcagga aatatagatc aaacaaagga 960

gaaagtcctg tggagcctgc agagccttgt cgttacagct gccccaggga ggaggagggc 1020

agcaccatcc ccatccagga ggattaccga aaaccggagc ctgcctgctc cccccgcgtg 1080

aaattcagcc gcagcgcaga tgctccagcc tacaagcagg ggcagaacca gctctacaac 1140

gaactcaatc ttggtcggag agaggagtac gacgtgctgg acaagcggag aggacgggac 1200

ccagaaatgg gcgggaagcc gcgcagaaag aatccccaag agggcctgta caacgagctc 1260

caaaaggata agatggcaga agcctatagc gagattggta tgaaagggga acgcagaaga 1320

ggcaaaggcc acgacggact gtaccaggga ctcagcaccg ccaccaagga cacctatgac 1380

gctcttcaca tgcaggccct gccgcctcgg 1410

<210> 5

<211> 1470

<212> DNA

<213>artificial sequence (Artificial Sequence)

<400> 5

gccctgcctg tgacagccct gctgctgcct ctggctctgc tgctgcatgc cgctagaccc 60

gaggtgaagc tggtggagtc tggaggaggc ttggtacagc ctgggggttc tctgagactc 120

tcctgtgcaa cttctgggtt cacgttctct gattactaca tggcctgggt ccgccagcct 180

ccaggaaagg cacttgagtg gttgggttta attagaaaca aaggtaatgg ttacacaaca 240

gagcacagtg catctgtgag gggtcggttc accatctcca gagataattc ccaaagcatc 300

ctctatcttc aaatgaacac cctgagacct gaggacagtg ccacttatta ctgtgcaaga 360

gattaccggt ctatggacta ctggggcgca ggaactatag tcacagtcaa tggtggcggt 420

ggctcgggcg gtggtgggtc gggtggcggc ggatctgaca ttgtgctcac acaatctaca 480

ccttctttgg ctgtgtctct agggcagagg gccaccatat cctgcagagc cagtgaaagt 540

gttgatagtt atggcaacag ttttatgcac tggttccagc agaaaccagg acagccaccc 600

aaactcctca tctatcgtgc atccaaccta gaatctggga tccctgccag gttcagtggc 660

agtgggtcta ggacagactt caccctcacc attaatcctg tggaggctga tgatgttgca 720

acctattact gtcagcaaag taatgaggat ccgtacacgt tcggaggggg gaccaagctg 780

gaaataaaaa ccacgacgcc agcgccgcga ccaccaacac cggcgcccac catcgcgtcg 840

cagcccctgt ccctgcgccc agaggcgtgc cggccagcgg cggggggcgc agtgcacacg 900

agggggctgg acttcgcctg tgatatctac atctgggcgc ccttggccgg gacttgtggg 960

gtccttctcc tgtcactggt tatcaccctt tactgcagga aatatagatc aaacaaagga 1020

gaaagtcctg tggagcctgc agagccttgt cgttacagct gccccaggga ggaggagggc 1080

agcaccatcc ccatccagga ggattaccga aaaccggagc ctgcctgctc cccccgcgtg 1140

aaattcagcc gcagcgcaga tgctccagcc tacaagcagg ggcagaacca gctctacaac 1200

gaactcaatc ttggtcggag agaggagtac gacgtgctgg acaagcggag aggacgggac 1260

ccagaaatgg gcgggaagcc gcgcagaaag aatccccaag agggcctgta caacgagctc 1320

caaaaggata agatggcaga agcctatagc gagattggta tgaaagggga acgcagaaga 1380

ggcaaaggcc acgacggact gtaccaggga ctcagcaccg ccaccaagga cacctatgac 1440

gctcttcaca tgcaggccct gccgcctcgg 1470

<210> 6

<211> 729

<212> DNA

<213>artificial sequence (Artificial Sequence)

<400> 6

gaggtgaagc tggtggagtc tggaggaggc ttggtacagc ctgggggttc tctgagactc 60

tcctgtgcaa cttctgggtt cacgttctct gattactaca tggcctgggt ccgccagcct 120

ccaggaaagg cacttgagtg gttgggttta attagaaaca aaggtaatgg ttacacaaca 180

gagcacagtg catctgtgag gggtcggttc accatctcca gagataattc ccaaagcatc 240

ctctatcttc aaatgaacac cctgagacct gaggacagtg ccacttatta ctgtgcaaga 300

gattaccggt ctatggacta ctggggcgca ggaactatag tcacagtcaa tggtggcggt 360

ggctcgggcg gtggtgggtc gggtggcggc ggatctgaca ttgtgctcac acaatctaca 420

ccttctttgg ctgtgtctct agggcagagg gccaccatat cctgcagagc cagtgaaagt 480

gttgatagtt atggcaacag ttttatgcac tggttccagc agaaaccagg acagccaccc 540

aaactcctca tctatcgtgc atccaaccta gaatctggga tccctgccag gttcagtggc 600

agtgggtcta ggacagactt caccctcacc attaatcctg tggaggctga tgatgttgca 660

acctattact gtcagcaaag taatgaggat ccgtacacgt tcggaggggg gaccaagctg 720

gaaataaaa 729

<210> 7

<211> 45

<212> PRT

<213>artificial sequence (Artificial Sequence)

<400> 7

Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala

1 5 10 15

Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly

20 25 30

Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp

35 40 45

<210> 8

<211> 135

<212> DNA

<213>artificial sequence (Artificial Sequence)

<400> 8

accacgacgc cagcgccgcg accaccaaca ccggcgccca ccatcgcgtc gcagcccctg 60

tccctgcgcc cagaggcgtg ccggccagcg gcggggggcg cagtgcacac gagggggctg 120

gacttcgcct gtgat 135

<210> 9

<211> 24

<212> PRT

<213>artificial sequence (Artificial Sequence)

<400> 9

Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu

1 5 10 15

Ser Leu Val Ile Thr Leu Tyr Cys

20

<210> 10

<211> 72

<212> DNA

<213>artificial sequence (Artificial Sequence)

<400> 10

atctacatct gggcgccctt ggccgggact tgtggggtcc ttctcctgtc actggttatc 60

accctttact gc 72

<210> 11

<211> 138

<212> DNA

<213>artificial sequence (Artificial Sequence)

<400> 11

aggaaatata gatcaaacaa aggagaaagt cctgtggagc ctgcagagcc ttgtcgttac 60

agctgcccca gggaggagga gggcagcacc atccccatcc aggaggatta ccgaaaaccg 120

gagcctgcct gctccccc 138

<210> 12

<211> 112

<212> PRT

<213>artificial sequence (Artificial Sequence)

<400> 12

Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly

1 5 10 15

Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr

20 25 30

Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys

35 40 45

Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys

50 55 60

Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg

65 70 75 80

Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala

85 90 95

Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg

100 105 110

<210> 13

<211> 336

<212> DNA

<213>artificial sequence (Artificial Sequence)

<400> 13

cgcgtgaaat tcagccgcag cgcagatgct ccagcctaca agcaggggca gaaccagctc 60

tacaacgaac tcaatcttgg tcggagagag gagtacgacg tgctggacaa gcggagagga 120

cgggacccag aaatgggcgg gaagccgcgc agaaagaatc cccaagaggg cctgtacaac 180

gagctccaaa aggataagat ggcagaagcc tatagcgaga ttggtatgaa aggggaacgc 240

agaagaggca aaggccacga cggactgtac cagggactca gcaccgccac caaggacacc 300

tatgacgctc ttcacatgca ggccctgccg cctcgg 336

<210> 14

<211> 20

<212> PRT

<213>artificial sequence (Artificial Sequence)

<400> 14

Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu His

1 5 10 15

Ala Ala Arg Pro

20

<210> 15

<211> 60

<212> DNA

<213>artificial sequence (Artificial Sequence)

<400> 15

gccctgcctg tgacagccct gctgctgcct ctggctctgc tgctgcatgc cgctagaccc 60

Claims

1. a kind of Chimeric antigen receptor T cell for targeting CD317, which is characterized in that the Chimeric antigen receptor including targeting CD317 CAR-CD317, the CAR-CD317 include the single-chain antibody, extracellular of the sequentially connected targeting CD317 from aminoterminal to c-terminus The amino acid sequence of hinge area, transmembrane region and intracellular signal area, wherein the single-chain antibody of the targeting CD317 includes such as SEQ Amino acid sequence shown in ID NO:1, the intracellular signal area include the sequentially connected CD27 signal from aminoterminal to c-terminus Area and CD3 ζ signaling zone, the amino acid sequence of the CD27 signaling zone include the amino acid sequence as shown in SEQ ID NO:2.

2. the Chimeric antigen receptor T cell of targeting CD22 as described in claim 1, which is characterized in that the extracellular hinge area Including CD8 α hinge area, the transmembrane region includes CD8 transmembrane region.

3. the Chimeric antigen receptor T cell of targeting CD317 as claimed in claim 2, which is characterized in that the CAR-CD317 Amino acid sequence include the amino acid sequence as shown in SEQ ID NO:3.

4. the Chimeric antigen receptor T cell of targeting CD22 as claimed in claim 3, which is characterized in that the CAR-CD317's Coding gene sequence includes the nucleotide sequence as shown in SEQ ID NO:4.

5. a kind of recombinant viral vector, which is characterized in that the recombinant viral vector includes as described in claim any one of 1-4 Targeting CD317 Chimeric antigen receptor T cell CAR-CD317 coding gene sequence.

6. recombinant viral vector as claimed in claim 5, which is characterized in that the coding gene sequence packet of the CAR-CD317 Include the nucleotide sequence as shown in SEQ ID NO:5.

7. a kind of host cell, which is characterized in that the host cell includes such as the described in any item recombination diseases of claim 5-6 Poisonous carrier.

8. a kind of preparation method for the Chimeric antigen receptor T cell for targeting CD317 characterized by comprising

(1) encoding gene of the Chimeric antigen receptor CAR-CD317 of targeting CD317 is provided, including is sequentially connected from 5 ' ends to 3 ' ends The encoding gene of the signal peptide connect, the encoding gene of single-chain antibody, the encoding gene of extracellular hinge area, cross-film for targeting CD317 The encoding gene in area and the encoding gene in intracellular signal area；Wherein, the single-chain antibody of the targeting CD317 is anti-for Humanized single chain The encoding gene of body, the single-chain antibody of the targeting CD317 includes the core for encoding the amino acid sequence as shown in SEQ ID NO:1 Nucleotide sequence；The encoding gene in the intracellular signal area includes the coding base from 5 ' ends to 3 ' the sequentially connected CD27 signaling zones in end The encoding gene of cause and CD3 ζ signaling zone, the encoding gene of the CD27 signaling zone include coding as shown in SEQ ID NO:2 The nucleotide sequence of amino acid sequence；

(2) encoding gene of the CAR-CD317 is inserted into pWPXLD carrier, obtains pWPXLD-CAR-CD317 recombination matter Grain；

(3) by the pWPXLD-CAR-CD317 recombinant plasmid and envelope plasmid, packaging plasmid cotransfection host cell, weight is obtained Group slow virus；

(4) recombinant slow virus is transfected into CD3 positive t lymphocytes, obtains the Chimeric antigen receptor T cell of targeting CD317.

9. the preparation method of the Chimeric antigen receptor T cell of targeting CD317 as claimed in claim 8, which is characterized in that described The coding gene sequence of CAR-CD317 includes the nucleotide sequence as shown in SEQ ID NO:5.

10. a kind of as claim 3-4 is described in any item or as made from the described in any item preparation methods of claim 8-9 Target the Chimeric antigen receptor T cell of CD317 or such as the described in any item recombinant viral vectors of claim 5-6 or such as right It is required that application of the host cell described in 7 in preparation prevention, diagnosing and treating malignant tumor medicine.